IL17A blockade with ixekizumab suppresses MuvB signaling in clinical psoriasis. Ochsner SA, Pedroza M, Pillich RT, Krishnan V, et al. J Invest Dermatol 2023 Mar 24:S0022-202X(23)01941.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ochsner SA, Pedroza M, Pillich RT, Krishnan V, et al. IL17A blockade with ixekizumab suppresses MuvB signaling in clinical psoriasis. J Invest Dermatol 2023 Mar 24:S0022-202X(23)01941.
PMID: 36967086